Brief: PDS Biotech Announces Updated Results From Versatile-002 Phase 2 Clinical Trial Presented At Esmo 2024
16/09/2024 12:39
Sept 16 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH ANNOUNCES UPDATED RESULTS FROM VERSATILE-002
PHASE 2
CLINICAL TRIAL PRESENTED AT ESMO 2024
* PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL AT 30
MONTHS,
ORR 36%, DCR 77%
Source text for Eikon: ID:nGNX1hSQMn
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing